Core Viewpoint - The company has submitted a confidential F-1 registration statement to the U.S. Securities and Exchange Commission for a proposed dual listing in the U.S., which is a significant step in its global strategy and is expected to bring multiple positive impacts [1] Group 1: Global Financing and Market Expansion - The dual listing is anticipated to expand the company's global financing channels by entering one of the largest and most comprehensive capital markets, potentially attracting more long-term international investors focused on biotechnology and healthcare [1] - This move is expected to provide strong capital support for the company's future research and commercialization efforts [1] Group 2: Brand and Market Presence - Listing on NASDAQ is expected to enhance the company's international brand influence, improving its corporate image and industry recognition in global markets [1] - It will also increase opportunities for communication and collaboration with potential global partners, clients, and regulatory bodies [1] Group 3: Share Liquidity and Valuation - The establishment of a cross-market trading mechanism is likely to broaden the investor base and enhance overall share liquidity [1] - This international pricing environment is expected to better reflect the company's long-term value [1] Group 4: Governance and Compliance - Adhering to U.S. securities regulations and disclosure requirements is projected to improve the company's governance standards and operational transparency [1] - This will strengthen the company's compliance image and investor trust on a global scale [1] Group 5: Strategic Flexibility - The dual listing structure will provide the company with a richer platform for capital operations and strategic options for future international collaborations, mergers, and business expansions [1]

Core Viewpoint - The company has decided to pursue a dual primary listing on the NASDAQ stock market through an initial public offering of American Depositary Shares, which is a significant step in its global strategic layout, expected to bring multiple positive impacts. Group 1: Global Financing and Market Expansion - The dual listing is anticipated to expand the company's global financing channels by entering one of the largest and most comprehensive capital markets, potentially attracting more long-term international investors focused on biotechnology and healthcare [1]. - This move is expected to provide strong capital support for the company's future research and commercialization efforts [1]. Group 2: Brand and Market Presence - Listing on NASDAQ will enhance the company's international brand influence, improving its corporate image and industry recognition in the global market [1]. - It will also increase opportunities for communication and collaboration with potential global partners, clients, and regulatory bodies [1]. Group 3: Share Liquidity and Valuation - The establishment of a cross-market trading mechanism is expected to broaden the investor base and enhance overall share liquidity [1]. - This environment will allow the company's long-term value to be fully reflected in a more international pricing context [1]. Group 4: Governance and Transparency - Adhering to U.S. securities regulations and disclosure requirements will improve the company's governance standards and operational transparency [1]. - This compliance is likely to strengthen the company's global compliance image and investor trust [1]. Group 5: Strategic Flexibility - The dual listing structure will provide the company with greater flexibility for future international collaborations, mergers, and business expansions, offering a richer platform for capital operations and strategic choices [2].

Core Viewpoint - The company, Huajian Medical, has proposed a dual primary listing on the NASDAQ stock market through the issuance of new ordinary shares in the form of American Depositary Shares, with a confidential F-1 registration statement submitted to the SEC on September 29, 2025. This move is part of the company's global strategic layout and is expected to bring multiple positive impacts. Group 1: Strategic Impacts - Expanding global financing channels: Entering one of the largest and most comprehensive capital markets globally is expected to attract more long-term international investors focused on biotechnology and healthcare, providing strong capital support for future R&D and commercialization [1] - Enhancing international brand influence: Listing on NASDAQ will further enhance the company's corporate image and industry recognition in international markets, increasing opportunities for communication and collaboration with global partners, clients, and regulatory bodies [1] - Increasing share liquidity and valuation potential: Establishing a cross-market trading mechanism will help expand the investor base, improve overall share liquidity, and reflect the company's long-term value in a more international pricing environment [1] - Optimizing corporate governance and transparency: Adhering to U.S. securities regulations and disclosure requirements will enhance the company's governance standards and operational transparency, strengthening its compliance image and investor trust globally [1] Group 2: Future Strategic Flexibility - Providing flexibility for future strategic advancement: The dual listing structure offers a richer capital operation platform and strategic options for potential international cooperation, mergers, and business expansion [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何 責 任。 本 公 告 僅 作 參 考 用 途，並 不 構 成 在 香 港 或 任 何 其 他 地 方 收 購、購 買 或 認 購 任 何 證 券 的 任 何 邀 請 或 要 約，本 公 告（或 其 任 何 部 分）或 分 發 本 公 告 之 事 實 亦 不 會 構 成 任 何 認 購 證 券 合 約 或 邀 請 的 基 準 或 有 關 依 據，且 僅 供 說 明 用 途。分 發 本 公 告 可 能 在 若 干 司 法 管 轄 區 受 到 法 律 限 制，而 獲 得 本 公 告 所 述 資 料 的 人 士 應 自 行 了 解 及 遵 守 任 何 該 等 限 制。任 何 未 能 遵 守 此 等 限 制 之 情 況 可 能 構 成 任 何 有 關 司 法 管 轄 區 的 違 法 行 為。本 公 告 所 述 的 證 券 尚 未 根 據 任 何 證 券 法 律 及 規 ...

(Stock Code: 1931) NOTIFICATION LETTER 通知信函 30 September 2025 Dear Non-registered Holder(s) (Note 1) , IVD Medical Holding Limited (the "Company") － Notice of publication of Interim Report 2025 (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's website at www.ivdholding.com and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at www.hkexnews.hk respectively (the "Website Versio ...

IVD Medical Holding Limited (the "Company") – Notice of publication of Interim Report 2025 (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are now available on the Company's website at www.ivdholding.com and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at www.hkexnews.hk respectively (the "Website Version"). The Company strongly recommends you to access the Website Version of the Current Corporate Com ...

IVD MEDICAL HOLDING LIMITED 華 檢 醫 療 控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） 股份代號：1931 中期報告 2025 IVD MEDICAL HOLDING LIMITED 華 檢 醫 療 控 股 有 限 公 司 Stock Code: 1931 (Incorporated in the Cayman Islands with limited liability) Interim Report 2025 | 公司資料 | 2 | | --- | --- | | 財務摘要 | 4 | | 管理層討論及分析 | 6 | | 中期簡明綜合損益及其他全面收益表 | 30 | | 中期簡明綜合財務狀況表 | 32 | | 中期簡明綜合權益變動表 | 34 | | 中期簡明綜合現金流量表 | 36 | | 中期簡明綜合財務資料附註 | 38 | | 其他資料 | 57 | 公司資料 董事 執行董事 2025 Interim Report 中期報告 IVD MEDICAL HOLDING LIMI TED 華檢醫療控股有限公司 目錄 何鞠誠先生 （自二零二五年七月一日辭任 ...

Core Viewpoint - Chuangsheng Group-B (06628) has seen a significant stock price increase of over 10%, currently trading at 4.82 HKD, following the announcement of a strategic cooperation agreement with Huajian Medical (01931) regarding the potential tokenization of innovative drug pipeline assets [1] Group 1: Strategic Cooperation - Chuangsheng Group has entered into a strategic cooperation agreement with Huajian Medical to explore the tokenization of its innovative drug pipeline assets [1] - The agreement involves integrating six core innovative drug pipeline assets (TST003, TST005, TST786, TST105, TST106, and TST013) into its U.S. entity [1] - The collaboration aims to utilize Huajian Medical's ETHK global innovative drug intellectual property RWA exchange for potential RWA tokenization [1] Group 2: Funding and Development - If the token issuance is successful, the proceeds will be used to accelerate the clinical and preclinical development of several innovative antibody projects targeting tumors [1] - The Chairman of Chuangsheng Group, Dr. Qian Xueming, emphasized the need for substantial funding in the long and high-risk process of drug development [1] - The partnership with Huajian Medical's on-chain RWA digital platform will provide a new funding channel by allowing the intellectual property of innovative drug pipelines to be packaged into a U.S. SPV for novel financing [1]

Major Events - Different Group (06090) has a public offering with a subscription rate of 3317.47 times the upper limit price [1] - Botai Che Lian (02889) plans to globally offer 10.4369 million H-shares from September 22 to September 25 [1] - Changhong Jiahua (03991) received a privatization offer from Changhong Group at a premium of approximately 32.93%, with resumption of trading on September 23 [1] - Huajian Medical (01931) signed a strategic cooperation agreement with Chuangsheng Group-B (06628) involving the tokenization of a $1.5 billion innovative drug pipeline asset [1] - Gilead Sciences-B (01672) reported that ASC47 combined with Semaglutide showed a weight loss effect improvement of up to 56.2% compared to Semaglutide alone in obese subjects [1] - Fosen Pharmaceutical (01652) plans to sell all equity of Henan Fosen Smart Energy Technology for 73 million yuan [1] - Maiyue Technology (02501) entered into strategic cooperation agreements with NetEase Youdao and Ferry International [1] - Zhongchuang Zhiling (00564) intends to invest 270 million yuan to establish Yaxinke Thermal Management Technology (Yizheng) Co., Ltd. to enhance market competitiveness in automotive thermal management systems [1] - Garmin Group Holdings (01271) plans to sell a portfolio of four data center projects for 5.25 billion HKD [1] Buybacks and Increases - Tencent Holdings (00700) repurchased 862,000 shares for 550 million HKD on September 22 [1] - Standard Chartered Group (02888) repurchased 517,100 shares for 7.3877 million GBP on September 19 [1] - Midea Group (00300) repurchased 3.415 million A-shares for 250 million yuan on September 22 [1] - Anta Sports (02020) repurchased 2.12 million shares for 199 million HKD on September 22 [1] - Kuaishou-W (01024) repurchased 1 million shares for 73.7998 million HKD on September 22 [1] - Heng Rui Pharmaceutical (01276) repurchased 656,000 A-shares for 45.7493 million yuan on September 19 [1] - Shenzhen Expressway Company (00548) received an increase of 25.38 million H-shares from shareholder Yunsong Capital [1]

Core Insights - The establishment of the ETHK building by Huajian Medical marks a significant milestone in the development of Real World Asset (RWA) digital technology, positioning Nanjing as a global hub for RWA technology [1][2] - Huajian Medical's strategy focuses on transforming into a digital infrastructure provider, with the ETHK building serving as a physical manifestation of this strategy [2][3] Group 1: RWA Technology and Nanjing Hub - RWA, or Real World Asset tokenization, is emerging as a hot area in global fintech, with a projected total locked value (TVL) of $12.5 billion by June 2025, representing a 124% increase from 2024 [2] - The establishment of ETHK Inc. and ETHK HOLDINGS LIMITED indicates Huajian Medical's commitment to the digital industry infrastructure [2] - Nanjing's location is strategic, as the Yangtze River Delta is a core area for China's biopharmaceutical industry, accounting for one-third of the national industry scale [2] Group 2: Strategic Collaborations - Huajian Medical signed strategic cooperation agreements with four companies, including a $1.5 billion RWA tokenization deal with Chuangsheng Group for six innovative drug pipeline assets [4][7] - The collaboration with Chuangsheng Group aims to integrate their innovative drug assets into a U.S. entity for potential RWA tokenization [4] - Additional partnerships with Shenzhen Yuanli Life Sciences, Jiangsu Mailian Technology, and Beijing Guofeng Law Firm create a comprehensive ecosystem from biopharmaceutical innovation to legal compliance [7] Group 3: Industry Transformation and Market Potential - The launch of the RWA technology base and strategic partnerships signify the scaling of Huajian Medical's ETHK chain financial ecosystem [8] - The global RWA market is projected to reach $16.1 trillion by 2030, representing 10% of global GDP [8] - RWA tokenization in the biopharmaceutical sector allows for the early locking of R&D value, providing new funding channels without equity dilution [8][9] Group 4: Altruistic Ecosystem and New Economic Paradigm - Huajian Medical's "altruistic" approach enables partners to optimize asset structures and innovate financing models [9] - The ETHK building's opening symbolizes a new economic paradigm, enhancing asset liquidity and capital allocation efficiency [10] - The digital economy wave signifies the beginning of a new era for global asset circulation in China [10]